• 한국식품과학회지
• /
• 제29권1호
• /
• pp.156-160
• /
• 1997

식용버섯류들의 MAO 저해활성을 검색할 목적으로 몇가지 유기용매를 이용하여 추출분획을 조제하고 이들의 MAO에 대한 저해활성을 검색하였다. 검색된 3종 버섯류의 유기용매 추출물들은 영지버섯 bud의 $CHCl_3$ 층을 제외하고는 모두 MAO-A에 대한 저해활성이 나타나지 않았으나 영지 bud의 경우 $CHCl_3$ 층에서 비교적 강력한 MAO-A 저해활성을 나타내어 영지 bud의 항암활성이 영지의 항암활성과 비교하여 더욱 강력하다는 기존의 보고와 관련하여 아주 흥미로운 결과로 영지의 성분연구에 아주 중요한 단서를 제공해 줄 것으로 생각된다. 또한 검색된 3종 버섯류의 유기용매 추출물들은 영지 bud, 표고버섯의 EtOAc 층에서 각각 51.3, 55.9%로 역한 정도의 저해활성이 관찰되었으며 그 외의 다른 버섯류들에서는 전혀 MAO-B에 대한 저해활성이 확인되지 않았다. 또한 영지버섯의 경우, $CHCl_3$ 층, EtOAc 층, $H_2O$ 층 모두에서 아주 미약하나마 MAO-B에 대한 저해활성을 나타냈으나 영지 bud의 경우 $CHCl_3$ 층에서 전혀 MAO-B에 대한 저해활성을 나타내지 않고 EtOAc 층에서 약한 MAO-B에 대한 저해활성이 확인되어 MAO-A와 MAO-B에 대한 영지버섯의 작용성분이 다른 성분일 것으로 추측된다.

• The Korean Journal of Pain
• /
• 제29권3호
• /
• pp.164-171
• /
• 2016

Background: Nefopam has been known as an inhibitor of the reuptake of monoamines, and the noradrenergic and/or serotonergic system has been focused on as a mechanism of its analgesic action. Here we investigated the role of the spinal dopaminergic neurotransmission in the antinociceptive effect of nefopam administered intravenously or intrathecally. Methods: The effects of intravenously and intrathecally administered nefopam were examined using the rat formalin test. Then we performed a microdialysis study to confirm the change of extracellular dopamine concentration in the spinal dorsal horn by nefopam. To determine whether the changes of dopamine level are associated with the nefopam analgesia, its mechanism was investigated pharmacologically via pretreatment with sulpiride, a dopaminergic D2 receptor antagonist. Results: When nefopam was administered intravenously the flinching responses in phase I of the formalin test were decreased, but not those in phase II of the formalin test were decreased. Intrathecally injected nefopam reduced the flinching responses in both phases of the formalin test in a dose dependent manner. Microdialysis study revealed a significant increase of the level of dopamine in the spinal cord by intrathecally administered nefopam (about 3.8 fold the baseline value) but not by that administered intravenously. The analgesic effects of intrathecally injected nefopam were not affected by pretreatment with sulpiride, and neither were those of the intravenous nefopam. Conclusions: Both the intravenously and intrathecally administered nefopam effectively relieved inflammatory pain in rats. Nefopam may act as an inhibitor of dopamine reuptake when delivered into the spinal cord. However, the analgesic mechanism of nefopam may not involve the dopaminergic transmission at the spinal level.

• The Korean Journal of Pain
• /
• 제26권1호
• /
• pp.14-20
• /
• 2013

Background: Nefopam, a non-opiate analgesic, has been regarded as a substance that reduces the requirement for morphine, but conflicting results have also been reported. The inhibition of monoamine reuptake is a mechanism of action for the analgesia of nefopam. The spinal cord is an important site for the action of monoamines however, the antinociceptive effect of intrathecal nefopam was not clear. This study was performed to examine the antinociceptive effect of intrathecal (i.t.) nefopam and the pattern of pharmacologic interaction with i.t. morphine in the formalin test. Methods: Male Sprague-Dawley rats were implanted with an i.t. catheter, and were randomly treated with a vehicle, nefopam, or morphine. Formalin was injected into the hind-paw 10 min. after an i.t. injection of the above experiment drugs. After obtaining antinociceptive $ED_{50}$ of nefopam and morphine, the mixture of nefopam and morphine was tested for the antinociceptive effect in the formalin test at a dose of 1/8, 1/4, 1/2 of $ED_{50}$, or $ED_{50}$ of each drug followed by an isobolographic analysis. Results: Intrathecal nefopam significantly reduced the flinching responses in both phases of the formalin test in a dose-dependent manner. Its effect, however, peaked at a dose of $30{\mu}g$ in phase 1 (39.8% of control) and $10{\mu}g$ during phase 2 (37.6% of control). The isobolograhic analysis indicated an additive interaction of nefopam and morphine during phase 2, and a synergy effect in antinociception during phase 1. Conclusions: This study demonstrated that i.t. nefopam produces an antinociceptive effect in formalin induced pain behavior during both phases of the formalin test, while interacting differently with i.t. morphine, synergistically during phase 1, and additively during phase 2.

• 동의신경정신과학회지
• /
• 제30권3호
• /
• pp.209-220
• /
• 2019

Objectives: As a general emotion, everyone can temporarily experience depression, but depressive disorder is a disease that excessively affects daily life. Among the various causes of depression, the deficiency of monoamine-based neurotransmitters such as serotonin and epinephrine are considered significant. Thus, antidepressants that target monoamines are used frequently. However, side effects such as nausea, vomiting, insomnia, anxiety, and sexual dysfunction are observed. Thus, it is necessary to develop a new therapeutic agent with fewer side effects. In this study, we investigated the antidepressant effect of JG02, used to treat depression by normalizing the flow of qi (氣) in Korean medicine. Methods: C57BL/6 mice were selected and randomly divided into six groups: normal, control, amitriptyline, and JG02 (50, 125, 250 mg/kg), respectively. Except for normal, depression was induced by applying restraint stress at the same time for six hours daily for 14 consecutive days. Saline, amitriptyline or JG02 samples were orally administered two hours before applying the stress. After that, a forced swimming test and an open field test were performed. Additionally, serum corticosterone, serotonin mRNA, BDNF mRNA, and protein in the hippocampal region were measured and compared. Results: JG02 decreased immobility time rate in the FST and increased the zone transition number and travel distance in the OFT. Also, JG02 inhibited the release of serum corticosterone, and increased serotonin, BDNF gene expression, and BDNF protein in the hippocampus. Conclusions: In this study, JG02 showed significant antidepressant effects on the chronic restraint stress mice model. When further research is performed based on JG02, the development of a new antidepressant is considered highly possible.